Natalizumab exerts direct signaling capacity and supports a pro-inflammatory phenotype in some patients with multiple sclerosis.

por Thomas F Benkert, Lena Dietz, Elena M Hartmann, Ellen Leich, Andreas Rosenwald, Edgar Serfling, Mathias Buttmann, Friederike Berberich-Siebelt
Publicado 2012

NFATc1 supports imiquimod-induced skin inflammation by suppressing IL-10 synthesis in B cells

por Hani Alrefai, Khalid Muhammad, Ronald Rudolf, Duong Anh Thuy Pham, Stefan Klein-Hessling, Amiya K. Patra, Andris Avots, Valesca Bukur, Ugur Sahin, Stefan Tenzer, Matthias Goebeler, Andreas Kerstan, Edgar Serfling
Publicado 2016

Correction: Corrigendum: NFATc1 supports imiquimod-induced skin inflammation by suppressing IL-10 synthesis in B cells

por Hani Alrefai, Khalid Muhammad, Ronald Rudolf, Duong Anh Thuy Pham, Stefan Klein-Hessling, Amiya K. Patra, Andris Avots, Valesca Bukur, Ugur Sahin, Stefan Tenzer, Matthias Goebeler, Andreas Kerstan, Edgar Serfling
Publicado 2016

A threshold level of NFATc1 activity facilitates thymocyte differentiation and opposes notch-driven leukaemia development

por Stefan Klein-Hessling, Ronald Rudolf, Khalid Muhammad, Klaus-Peter Knobeloch, Muhammad Ahmad Maqbool, Pierre Cauchy, Jean-Christophe Andrau, Andris Avots, Claudio Talora, Volker Ellenrieder, Isabella Screpanti, Edgar Serfling, Amiya Kumar Patra
Publicado 2016

NFATc1 controls the cytotoxicity of CD8+ T cells

por Stefan Klein-Hessling, Khalid Muhammad, Matthias Klein, Tobias Pusch, Ronald Rudolf, Jessica Flöter, Musga Qureischi, Andreas Beilhack, Martin Vaeth, Carsten Kummerow, Christian Backes, Rouven Schoppmeyer, Ulrike Hahn, Markus Hoth, Tobias Bopp, Friederike Berberich-Siebelt, Amiya Patra, Andris Avots, Nora Müller, Almut Schulze, Edgar Serfling
Publicado 2017